Profil
Niels Reichardt worked as a Scientific Director at Metabolic Renal Disease SL and as a Group Leader at CICbiomagune institute.
He also worked as a Research Scientist at GlycoForm Ltd.
for a brief period.
He obtained a doctorate degree from Universität Konstanz.
Anciens postes connus de Niels Reichardt
| Sociétés | Poste | Fin |
|---|---|---|
GlycoForm Ltd.
 GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Directeur Technique/Scientifique/R&D | 01/01/2006 |
| CICbiomagune institute | Corporate Officer/Principal | - |
Metabolic Renal Disease SL
 Metabolic Renal Disease SL Medical SpecialtiesHealth Technology Metabolic Renal Disease SL develops mass-spectrometry based tools for targeted metabolomics. It is a biotechnology company that specializes in the field of biometrics. The company's activity is centered in the development of analytical tools based in mass spectrometry and oriented to metabolomics for the identification, quantification and interpretation of metabolites in biofluids. The firm offers a range of applications, specially related to toxicology and pharmacological evaluation. Metabolic Renal Disease was founded in 2008 and is headquartered in San Sebastian, Spain. | Directeur Technique/Scientifique/R&D | - |
Formation de Niels Reichardt
| Universität Konstanz | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Health Technology |
Metabolic Renal Disease SL
Metabolic Renal Disease SL Medical SpecialtiesHealth Technology Metabolic Renal Disease SL develops mass-spectrometry based tools for targeted metabolomics. It is a biotechnology company that specializes in the field of biometrics. The company's activity is centered in the development of analytical tools based in mass spectrometry and oriented to metabolomics for the identification, quantification and interpretation of metabolites in biofluids. The firm offers a range of applications, specially related to toxicology and pharmacological evaluation. Metabolic Renal Disease was founded in 2008 and is headquartered in San Sebastian, Spain. | Health Technology |
| CICbiomagune institute |
